Trazodona (Spanish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Trazodona" in Spanish language version.

refsWebsite

Global rank Spanish rank

38nih.gov

4^th place

21doi.org

2^nd place

4psychiatryonline.org

4,032^nd place

2,441^st place

3web.archive.org

1^st place

3elsevier.com

610^th place

332^nd place

3archive.org

6^th place

5^th place

3wkhealth.com

low place

4,276^th place

2aspetjournals.org

6,663^rd place

4,366^th place

1sagepub.com

731^st place

568^th place

1springer.de

low place

1informahealthcare.com

low place

8,850^th place

1vademecum.es

low place

3,373^rd place

archive.org

Marek GJ, McDougle CJ, Price LH, Seiden LS (1992). «A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action». Psychopharmacology 109 (1-2): 2-11. PMID 1365657. doi:10.1007/BF02245475.
Raffa RB, Shank RP, Vaught JL (1992). «Etoperidone, trazodone and MCPP: in vitro and in vivo identification of serotonin 5-HT1A (antagonistic) activity». Psychopharmacology 108 (3): 320-6. PMID 1387963. doi:10.1007/BF02245118.
Vetulani J, Sansone M, Baran L, Hano J (1984). «Opposite action of m-chlorophenylpiperazine on avoidance depression induced by trazodone and pimozide in CD-1 mice». Psychopharmacology 83 (2): 166-8. PMID 6431467. doi:10.1007/BF00429728.

aspetjournals.org

jpet.aspetjournals.org

Richelson E, Nelson A (julio de 1984). «Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro». The Journal of Pharmacology and Experimental Therapeutics 230 (1): 94-102. PMID 6086881.

dmd.aspetjournals.org

Rotzinger S, Fang J, Baker GB (1 de junio de 1998). «Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources». Drug Metab. Dispos. 26 (6): 572-5. PMID 9616194.

doi.org

dx.doi.org

Haria M, Fitton A, McTavish D (abril de 1994). «Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders». Drugs Aging 4 (4): 331-55. PMID 8019056. doi:10.2165/00002512-199404040-00006.
Hayashi T, Yokota N, Takahashi T (julio de 1997). «Benefits of trazodone and mianserin for patients with late-life chronic schizophrenia and tardive dyskinesia: an add-on, double-blind, placebo-controlled study». Int Clin Psychopharmacol 12 (4): 199-205. PMID 9347380. doi:10.1097/00004850-199707000-00003.
Le Bon O; Murphy JR; Staner L; Hoffmann G; Kormoss N; Kentos M; Dupont P; Lion K; Pelc I; Verbanck P (agosto de 2003). «Double-blind, placebo-controlled study of the efficacy of trazodone in alcohol post-withdrawal syndrome: polysomnographic and clinical evaluations». J Clin Psychopharmacol 23 (4): 377-83. PMID 12920414. doi:10.1097/01.jcp.0000085411.08426.d3.
Borras L; de Timary P, Constant EL, Huguelet P, Eytan A (noviembre de 2006). «Successful treatment of alcohol withdrawal with trazodone». Pharmacopsychiatry 39 (6): 232. PMID 17124647. doi:10.1055/s-2006-951385.
Kaynak H, Kaynak D, Gözükirmizi E, Guilleminault C (enero de 2004). «The effects of trazodone on sleep in patients treated with stimulant antidepressants». Sleep Med. 5 (1): 15-20. PMID 14725822. doi:10.1016/j.sleep.2003.06.006.
Pope HG, Keck PE, McElroy SL, Hudson JI (agosto de 1989). «A placebo-controlled study of trazodone in bulimia nervosa». J Clin Psychopharmacol 9 (4): 254-9. PMID 2671058. doi:10.1097/00004714-198908000-00004.
Prasad A (febrero de 1985). «Efficacy of trazodone as an anti obsessional agent». Pharmacol. Biochem. Behav. 22 (2): 347-8. PMID 3983224. doi:10.1016/0091-3057(85)90403-4.
Pigott TA, L'Heureux F, Rubenstein CS, Bernstein SE, Hill JL, Murphy DL (junio de 1992). «A double-blind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder». J Clin Psychopharmacol 12 (3): 156-62. PMID 1629380. doi:10.1097/00004714-199202000-00003.
Marek GJ, McDougle CJ, Price LH, Seiden LS (1992). «A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action». Psychopharmacology 109 (1-2): 2-11. PMID 1365657. doi:10.1007/BF02245475.
Watanabe N, Omori IM, Nakagawa A, et al. (enero de 2010). «Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis». CNS Drugs 24 (1): 35-53. PMID 20030418. doi:10.2165/11319480-000000000-00000.
Raffa RB, Shank RP, Vaught JL (1992). «Etoperidone, trazodone and MCPP: in vitro and in vivo identification of serotonin 5-HT1A (antagonistic) activity». Psychopharmacology 108 (3): 320-6. PMID 1387963. doi:10.1007/BF02245118.
Odagaki Y, Toyoshima R, Yamauchi T (mayo de 2005). «Trazodone and its active metabolite m-chlorophenylpiperazine as partial agonists at 5-HT1A receptors assessed by [35S]GTPgammaS binding». Journal of Psychopharmacology (Oxford, England) 19 (3): 235-41. PMID 15888508. doi:10.1177/0269881105051526.
Wander TJ, Nelson A, Okazaki H, Richelson E (diciembre de 1986). «Antagonism by antidepressants of serotonin S1 and S2 receptors of normal human brain in vitro». European Journal of Pharmacology 132 (2-3): 115-21. PMID 3816971. doi:10.1016/0014-2999(86)90596-0.
Cusack B, Nelson A, Richelson E (mayo de 1994). «Binding of antidepressants to human brain receptors: focus on newer generation compounds». Psychopharmacology 114 (4): 559-65. PMID 7855217. doi:10.1007/BF02244985.
Pälvimäki EP, Roth BL, Majasuo H, et al. (agosto de 1996). «Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor». Psychopharmacology 126 (3): 234-40. PMID 8876023. doi:10.1007/BF02246453.
Tatsumi M, Groshan K, Blakely RD, Richelson E (diciembre de 1997). «Pharmacological profile of antidepressants and related compounds at human monoamine transporters». European Journal of Pharmacology 340 (2-3): 249-58. PMID 9537821. doi:10.1016/S0014-2999(97)01393-9.
Maes M, Westenberg H, Vandoolaeghe E, et al. (octubre de 1997). «Effects of trazodone and fluoxetine in the treatment of major depression: therapeutic pharmacokinetic and pharmacodynamic interactions through formation of meta-chlorophenylpiperazine». Journal of Clinical Psychopharmacology 17 (5): 358-64. PMID 9315986. doi:10.1097/00004714-199710000-00004. Archivado desde el original el 16 de agosto de 2011. Consultado el 15 de abril de 2020.
Mihara K, Yasui-Furukori N, Kondo T, et al. (agosto de 2002). «Relationship between plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine, and its clinical effect in depressed patients». Therapeutic Drug Monitoring 24 (4): 563-6. PMID 12142643. doi:10.1097/00007691-200208000-00016. Archivado desde el original el 16 de agosto de 2011. Consultado el 15 de abril de 2020.
Li AA, Marek GJ, Hand TH, Seiden LS (febrero de 1990). «Antidepressant-like effects of trazodone on a behavioral screen are mediated by trazodone, not the metabolite m-chlorophenylpiperazine». European Journal of Pharmacology 177 (3): 137-44. PMID 2311675. doi:10.1016/0014-2999(90)90263-6.
Vetulani J, Sansone M, Baran L, Hano J (1984). «Opposite action of m-chlorophenylpiperazine on avoidance depression induced by trazodone and pimozide in CD-1 mice». Psychopharmacology 83 (2): 166-8. PMID 6431467. doi:10.1007/BF00429728.
Kast RE (2009). «Trazodone generates m-CPP: in 2008 risks from m-CPP might outweigh benefits of trazodone». The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry 10 (4 Pt 2): 682-5. PMID 19384678. doi:10.1080/15622970902836022.

elsevier.com

linkinghub.elsevier.com

Kaynak H, Kaynak D, Gözükirmizi E, Guilleminault C (enero de 2004). «The effects of trazodone on sleep in patients treated with stimulant antidepressants». Sleep Med. 5 (1): 15-20. PMID 14725822. doi:10.1016/j.sleep.2003.06.006.
Prasad A (febrero de 1985). «Efficacy of trazodone as an anti obsessional agent». Pharmacol. Biochem. Behav. 22 (2): 347-8. PMID 3983224. doi:10.1016/0091-3057(85)90403-4.
Tatsumi M, Groshan K, Blakely RD, Richelson E (diciembre de 1997). «Pharmacological profile of antidepressants and related compounds at human monoamine transporters». European Journal of Pharmacology 340 (2-3): 249-58. PMID 9537821. doi:10.1016/S0014-2999(97)01393-9.

informahealthcare.com

Kast RE (2009). «Trazodone generates m-CPP: in 2008 risks from m-CPP might outweigh benefits of trazodone». The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry 10 (4 Pt 2): 682-5. PMID 19384678. doi:10.1080/15622970902836022.

nih.gov

ncbi.nlm.nih.gov

Haria M, Fitton A, McTavish D (abril de 1994). «Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders». Drugs Aging 4 (4): 331-55. PMID 8019056. doi:10.2165/00002512-199404040-00006.
Silvestrini B (1989). «Trazodone: from the mental pain to the "dys-stress" hypothesis of depression». Clin Neuropharmacol 12 (Suppl 1): S4-10. PMID 2568177.
Hayashi T, Yokota N, Takahashi T (julio de 1997). «Benefits of trazodone and mianserin for patients with late-life chronic schizophrenia and tardive dyskinesia: an add-on, double-blind, placebo-controlled study». Int Clin Psychopharmacol 12 (4): 199-205. PMID 9347380. doi:10.1097/00004850-199707000-00003.
Decina P, Mukherjee S, Bocola V, Saraceni F, Hadjichristos C, Scapicchio P (diciembre de 1994). «Adjunctive trazodone in the treatment of negative symptoms of schizophrenia». Hosp Community Psychiatry 45 (12): 1220-3. PMID 7868106. Archivado desde el original el 20 de febrero de 2012. Consultado el 22 de abril de 2010.
Roccatagliata G; Albano C; Maffini M; Farelli S (1980). «Alcohol withdrawal syndrome: treatment with trazodone». Int Pharmacopsychiatry. 15 (2): 105-10. PMID 6108298.
Le Bon O; Murphy JR; Staner L; Hoffmann G; Kormoss N; Kentos M; Dupont P; Lion K; Pelc I; Verbanck P (agosto de 2003). «Double-blind, placebo-controlled study of the efficacy of trazodone in alcohol post-withdrawal syndrome: polysomnographic and clinical evaluations». J Clin Psychopharmacol 23 (4): 377-83. PMID 12920414. doi:10.1097/01.jcp.0000085411.08426.d3.
Borras L; de Timary P, Constant EL, Huguelet P, Eytan A (noviembre de 2006). «Successful treatment of alcohol withdrawal with trazodone». Pharmacopsychiatry 39 (6): 232. PMID 17124647. doi:10.1055/s-2006-951385.
Nierenberg AA, Adler LA, Peselow E, Zornberg G, Rosenthal M (julio de 1994). «Trazodone for antidepressant-associated insomnia». Am J Psychiatry 151 (7): 1069-72. PMID 8010365.
Kaynak H, Kaynak D, Gözükirmizi E, Guilleminault C (enero de 2004). «The effects of trazodone on sleep in patients treated with stimulant antidepressants». Sleep Med. 5 (1): 15-20. PMID 14725822. doi:10.1016/j.sleep.2003.06.006.
Scharf MB, Sachais BA (septiembre de 1990). «Sleep laboratory evaluation of the effects and efficacy of trazodone in depressed insomniac patients». J Clin Psychiatry 51 (Suppl): 13-7. PMID 2211559.
Mavissakalian M, Perel J, Bowler K, Dealy R (junio de 1987). «Trazodone in the treatment of panic disorder and agoraphobia with panic attacks». Am J Psychiatry 144 (6): 785-7. PMID 3296792.
Rickels K, Downing R, Schweizer E, Hassman H (noviembre de 1993). «Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam». Arch. Gen. Psychiatry 50 (11): 884-95. PMID 8215814.
Pope HG, Keck PE, McElroy SL, Hudson JI (agosto de 1989). «A placebo-controlled study of trazodone in bulimia nervosa». J Clin Psychopharmacol 9 (4): 254-9. PMID 2671058. doi:10.1097/00004714-198908000-00004.
Prasad A (febrero de 1985). «Efficacy of trazodone as an anti obsessional agent». Pharmacol. Biochem. Behav. 22 (2): 347-8. PMID 3983224. doi:10.1016/0091-3057(85)90403-4.
Pigott TA, L'Heureux F, Rubenstein CS, Bernstein SE, Hill JL, Murphy DL (junio de 1992). «A double-blind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder». J Clin Psychopharmacol 12 (3): 156-62. PMID 1629380. doi:10.1097/00004714-199202000-00003.
Marek GJ, McDougle CJ, Price LH, Seiden LS (1992). «A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action». Psychopharmacology 109 (1-2): 2-11. PMID 1365657. doi:10.1007/BF02245475.
Vanina Y, Podolskaya A, Sedky K, et al. (julio de 2002). «Body weight changes associated with psychopharmacology». Psychiatric Services (Washington, D.C.) 53 (7): 842-7. PMID 12096167.
Watanabe N, Omori IM, Nakagawa A, et al. (enero de 2010). «Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis». CNS Drugs 24 (1): 35-53. PMID 20030418. doi:10.2165/11319480-000000000-00000.
Raffa RB, Shank RP, Vaught JL (1992). «Etoperidone, trazodone and MCPP: in vitro and in vivo identification of serotonin 5-HT1A (antagonistic) activity». Psychopharmacology 108 (3): 320-6. PMID 1387963. doi:10.1007/BF02245118.
Odagaki Y, Toyoshima R, Yamauchi T (mayo de 2005). «Trazodone and its active metabolite m-chlorophenylpiperazine as partial agonists at 5-HT1A receptors assessed by [35S]GTPgammaS binding». Journal of Psychopharmacology (Oxford, England) 19 (3): 235-41. PMID 15888508. doi:10.1177/0269881105051526.
Kinney GG, Griffith JC, Hudzik TJ (julio de 1998). «Antidepressant-like effects of 5-hydroxytryptamine1A receptor agonists on operant responding under a response duration differentiation schedule». Behavioural Pharmacology 9 (4): 309-18. PMID 10065919.
Asayesh K (diciembre de 1986). «Combination of trazodone and phenothiazines: a possible additive hypotensive effect». Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie 31 (9): 857-8. PMID 3802006.
Richelson E, Nelson A (julio de 1984). «Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro». The Journal of Pharmacology and Experimental Therapeutics 230 (1): 94-102. PMID 6086881.
Wander TJ, Nelson A, Okazaki H, Richelson E (diciembre de 1986). «Antagonism by antidepressants of serotonin S1 and S2 receptors of normal human brain in vitro». European Journal of Pharmacology 132 (2-3): 115-21. PMID 3816971. doi:10.1016/0014-2999(86)90596-0.
Cusack B, Nelson A, Richelson E (mayo de 1994). «Binding of antidepressants to human brain receptors: focus on newer generation compounds». Psychopharmacology 114 (4): 559-65. PMID 7855217. doi:10.1007/BF02244985.
Pälvimäki EP, Roth BL, Majasuo H, et al. (agosto de 1996). «Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor». Psychopharmacology 126 (3): 234-40. PMID 8876023. doi:10.1007/BF02246453.
Tatsumi M, Groshan K, Blakely RD, Richelson E (diciembre de 1997). «Pharmacological profile of antidepressants and related compounds at human monoamine transporters». European Journal of Pharmacology 340 (2-3): 249-58. PMID 9537821. doi:10.1016/S0014-2999(97)01393-9.
Melzacka M, Rurak A, Vetulani J (1980). «Preliminary study of the biotransformation of two new drugs, trazodone and etoperidone». Polish Journal of Pharmacology and Pharmacy 32 (4): 551-6. PMID 7255270.
Fong MH, Garattini S, Caccia S (octubre de 1982). «1-m-Chlorophenylpiperazine is an active metabolite common to the psychotropic drugs trazodone, etoperidone and mepiprazole». The Journal of Pharmacy and Pharmacology 34 (10): 674-5. PMID 6128394.
Maes M, Westenberg H, Vandoolaeghe E, et al. (octubre de 1997). «Effects of trazodone and fluoxetine in the treatment of major depression: therapeutic pharmacokinetic and pharmacodynamic interactions through formation of meta-chlorophenylpiperazine». Journal of Clinical Psychopharmacology 17 (5): 358-64. PMID 9315986. doi:10.1097/00004714-199710000-00004. Archivado desde el original el 16 de agosto de 2011. Consultado el 15 de abril de 2020.
Mihara K, Yasui-Furukori N, Kondo T, et al. (agosto de 2002). «Relationship between plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine, and its clinical effect in depressed patients». Therapeutic Drug Monitoring 24 (4): 563-6. PMID 12142643. doi:10.1097/00007691-200208000-00016. Archivado desde el original el 16 de agosto de 2011. Consultado el 15 de abril de 2020.
Li AA, Marek GJ, Hand TH, Seiden LS (febrero de 1990). «Antidepressant-like effects of trazodone on a behavioral screen are mediated by trazodone, not the metabolite m-chlorophenylpiperazine». European Journal of Pharmacology 177 (3): 137-44. PMID 2311675. doi:10.1016/0014-2999(90)90263-6.
Vetulani J, Sansone M, Baran L, Hano J (1984). «Opposite action of m-chlorophenylpiperazine on avoidance depression induced by trazodone and pimozide in CD-1 mice». Psychopharmacology 83 (2): 166-8. PMID 6431467. doi:10.1007/BF00429728.
Kast RE (2009). «Trazodone generates m-CPP: in 2008 risks from m-CPP might outweigh benefits of trazodone». The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry 10 (4 Pt 2): 682-5. PMID 19384678. doi:10.1080/15622970902836022.
Workman EA, Tellian F, Short D (mayo de 1992). «Trazodone induction of migraine headache through mCPP». The American Journal of Psychiatry 149 (5): 712. PMID 1575270.
Rotzinger S, Fang J, Baker GB (1 de junio de 1998). «Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources». Drug Metab. Dispos. 26 (6): 572-5. PMID 9616194.
Jauch R, Kopitar Z, Prox A, Zimmer A (1976). «[Pharmacokinetics and metabolism of trazodone in man (author's transl)]» [Pharmacokinetics and metabolism of trazodone in man (author's transl)]. Arzneimittelforschung (en alemán) 26 (11): 2084-9. PMID 1037253.

nlm.nih.gov

por MedlinePlus (agosto de 2008). «Trazodona». Enciclopedia médica en español. Consultado el 22 de abril de 2010.

psychiatryonline.org

ps.psychiatryonline.org

Decina P, Mukherjee S, Bocola V, Saraceni F, Hadjichristos C, Scapicchio P (diciembre de 1994). «Adjunctive trazodone in the treatment of negative symptoms of schizophrenia». Hosp Community Psychiatry 45 (12): 1220-3. PMID 7868106. Archivado desde el original el 20 de febrero de 2012. Consultado el 22 de abril de 2010.
Vanina Y, Podolskaya A, Sedky K, et al. (julio de 2002). «Body weight changes associated with psychopharmacology». Psychiatric Services (Washington, D.C.) 53 (7): 842-7. PMID 12096167.

ajp.psychiatryonline.org

Nierenberg AA, Adler LA, Peselow E, Zornberg G, Rosenthal M (julio de 1994). «Trazodone for antidepressant-associated insomnia». Am J Psychiatry 151 (7): 1069-72. PMID 8010365.
Mavissakalian M, Perel J, Bowler K, Dealy R (junio de 1987). «Trazodone in the treatment of panic disorder and agoraphobia with panic attacks». Am J Psychiatry 144 (6): 785-7. PMID 3296792.

sagepub.com

jop.sagepub.com

Odagaki Y, Toyoshima R, Yamauchi T (mayo de 2005). «Trazodone and its active metabolite m-chlorophenylpiperazine as partial agonists at 5-HT1A receptors assessed by [35S]GTPgammaS binding». Journal of Psychopharmacology (Oxford, England) 19 (3): 235-41. PMID 15888508. doi:10.1177/0269881105051526.

springer.de

link.springer.de

Pälvimäki EP, Roth BL, Majasuo H, et al. (agosto de 1996). «Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor». Psychopharmacology 126 (3): 234-40. PMID 8876023. doi:10.1007/BF02246453.

vademecum.es

«Ficha técnica de trazodona en Vademecum».

web.archive.org

Decina P, Mukherjee S, Bocola V, Saraceni F, Hadjichristos C, Scapicchio P (diciembre de 1994). «Adjunctive trazodone in the treatment of negative symptoms of schizophrenia». Hosp Community Psychiatry 45 (12): 1220-3. PMID 7868106. Archivado desde el original el 20 de febrero de 2012. Consultado el 22 de abril de 2010.
Maes M, Westenberg H, Vandoolaeghe E, et al. (octubre de 1997). «Effects of trazodone and fluoxetine in the treatment of major depression: therapeutic pharmacokinetic and pharmacodynamic interactions through formation of meta-chlorophenylpiperazine». Journal of Clinical Psychopharmacology 17 (5): 358-64. PMID 9315986. doi:10.1097/00004714-199710000-00004. Archivado desde el original el 16 de agosto de 2011. Consultado el 15 de abril de 2020.
Mihara K, Yasui-Furukori N, Kondo T, et al. (agosto de 2002). «Relationship between plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine, and its clinical effect in depressed patients». Therapeutic Drug Monitoring 24 (4): 563-6. PMID 12142643. doi:10.1097/00007691-200208000-00016. Archivado desde el original el 16 de agosto de 2011. Consultado el 15 de abril de 2020.

wkhealth.com

meta.wkhealth.com

Maes M, Westenberg H, Vandoolaeghe E, et al. (octubre de 1997). «Effects of trazodone and fluoxetine in the treatment of major depression: therapeutic pharmacokinetic and pharmacodynamic interactions through formation of meta-chlorophenylpiperazine». Journal of Clinical Psychopharmacology 17 (5): 358-64. PMID 9315986. doi:10.1097/00004714-199710000-00004. Archivado desde el original el 16 de agosto de 2011. Consultado el 15 de abril de 2020.
Mihara K, Yasui-Furukori N, Kondo T, et al. (agosto de 2002). «Relationship between plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine, and its clinical effect in depressed patients». Therapeutic Drug Monitoring 24 (4): 563-6. PMID 12142643. doi:10.1097/00007691-200208000-00016. Archivado desde el original el 16 de agosto de 2011. Consultado el 15 de abril de 2020.

content.wkhealth.com

Watanabe N, Omori IM, Nakagawa A, et al. (enero de 2010). «Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis». CNS Drugs 24 (1): 35-53. PMID 20030418. doi:10.2165/11319480-000000000-00000.